<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37496071</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1756-6606</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>26</Day></PubDate></JournalIssue><Title>Molecular brain</Title><ISOAbbreviation>Mol Brain</ISOAbbreviation></Journal><ArticleTitle>Specific vulnerability of iPSC-derived motor neurons with TDP-43 gene mutation to oxidative stress.</ArticleTitle><Pagination><StartPage>62</StartPage><MedlinePgn>62</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">62</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13041-023-01050-w</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a disease that affects motor neurons and has a poor prognosis. We focused on TAR DNA-binding protein 43&#xa0;kDa (TDP-43), which is a common component of neuronal inclusions in many ALS patients. To analyze the contribution of TDP-43 mutations to ALS in human cells, we first introduced TDP-43 mutations into healthy human iPSCs using CRISPR/Cas9 gene editing technology, induced the differentiation of these cells into motor and sensory neurons, and analyzed factors that are assumed to be altered in or associated with ALS (cell morphology, TDP-43 localization and aggregate formation, cell death, TDP-43 splicing function, etc.). We aimed to clarify the pathological alterations caused solely by TDP-43 mutation, i.e., the changes in human iPSC-derived neurons with TDP-43 mutation compared with those with the same genetic background except TDP-43 mutation. Oxidative stress induced by hydrogen peroxide administration caused the death of TDP-43 mutant-expressing motor neurons but not in sensory neurons, indicating the specific vulnerability of human iPSC-derived motor neurons with TDP-43 mutation to oxidative stress. In our model, we observed aggregate formation in a small fraction of TDP-43 mutant-expressing motor neurons, suggesting that aggregate formation seems to be related to ALS pathology but not the direct cause of cell death. This study provides basic knowledge for elucidating the pathogenesis of ALS and developing treatments for the disease.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Onda-Ohto</LastName><ForeName>Asako</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Regenerative Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8461, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8461, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasegawa-Ogawa</LastName><ForeName>Minami</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Regenerative Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8461, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuno</LastName><ForeName>Hiromasa</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Regenerative Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8461, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8461, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shiraishi</LastName><ForeName>Tomotaka</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Regenerative Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8461, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8461, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bono</LastName><ForeName>Keiko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Regenerative Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8461, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8461, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hiraki</LastName><ForeName>Hiromi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Regenerative Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8461, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8461, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanegae</LastName><ForeName>Yumi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Core Research Facilities, Research Center for Medical Sciences, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8461, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iguchi</LastName><ForeName>Yasuyuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8461, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okano</LastName><ForeName>Hirotaka James</ForeName><Initials>HJ</Initials><Identifier Source="ORCID">0000-0003-4611-7098</Identifier><AffiliationInfo><Affiliation>Division of Regenerative Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8461, Japan. hjokano@jikei.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Brain</MedlineTA><NlmUniqueID>101468876</NlmUniqueID><ISSNLinking>1756-6606</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="Y">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Motor neuron</Keyword><Keyword MajorTopicYN="N">Oxidative stress</Keyword><Keyword MajorTopicYN="N">iPSC</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>27</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>26</Day><Hour>23</Hour><Minute>44</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37496071</ArticleId><ArticleId IdType="pmc">PMC10369818</ArticleId><ArticleId IdType="doi">10.1186/s13041-023-01050-w</ArticleId><ArticleId IdType="pii">10.1186/s13041-023-01050-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med. 2001;344(22):1688&#x2013;1700. doi: 10.1056/NEJM200105313442207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200105313442207</ArticleId><ArticleId IdType="pubmed">11386269</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Chi&#xf2; A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014;17(1):17&#x2013;23. doi: 10.1038/nn.3584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3584</ArticleId><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin A, Perera ND, Beart PM, Turner BJ, Shabanpoor F. Amyotrophic lateral sclerosis and autophagy: dysfunction and therapeutic targeting. Cells. 2020;9(11):1&#x2013;30. doi: 10.3390/cells9112413.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9112413</ArticleId><ArticleId IdType="pmc">PMC7694295</ArticleId><ArticleId IdType="pubmed">33158177</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad A, Bharathi V, Sivalingam V, Girdhar A, Patel BK. Molecular mechanisms of TDP-43 misfolding and pathology in amyotrophic lateral sclerosis. Front Mol Neurosci. 2019;12(February):1&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6382748</ArticleId><ArticleId IdType="pubmed">30837838</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S, Kaneko K, Yamanaka K. Accelerated disease onset with stabilized familial amyotrophic lateral sclerosis (ALS)-linked mutant TDP-43 proteins. J Biol Chem. 2013;288(5):3641&#x2013;3654. doi: 10.1074/jbc.M112.433615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.433615</ArticleId><ArticleId IdType="pmc">PMC3561582</ArticleId><ArticleId IdType="pubmed">23235148</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogawa MH, Okano HJ. Characterization of the upstream and intron promoters of the gene encoding TAR DNA-binding protein. Sci Rep. 2021;11(1):8720. doi: 10.1038/s41598-021-88015-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-88015-y</ArticleId><ArticleId IdType="pmc">PMC8062691</ArticleId><ArticleId IdType="pubmed">33888768</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu LS, Cheng W, Hou SC, Yan YT, Jiang ST, Shen CKJ. TDP-43, a neuro-pathosignature factor, is essential for early mouse embryogenesis. Genesis. 2010;48(1):56&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">20014337</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V, Phaneuf D, Bareil C, Robertson J, Rouleau GA, Kriz J, et al. Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments. Brain. 2011;134(9):2610&#x2013;2626. doi: 10.1093/brain/awr159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr159</ArticleId><ArticleId IdType="pubmed">21752789</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SL, Wu LS, Lee M, Chang CW, Cheng WC, Fang YS, et al. A robust TDP-43 knock-in mouse model of ALS. Acta Neuropathol Commun. 2020;5:1&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6975031</ArticleId><ArticleId IdType="pubmed">31964415</ArticleId></ArticleIdList></Reference><Reference><Citation>White MA, Kim E, Duffy A, Adalbert R, Phillips BU, Peters OM, et al. TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. Nat Neurosci. 2018;21(4):552&#x2013;563. doi: 10.1038/s41593-018-0113-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0113-5</ArticleId><ArticleId IdType="pmc">PMC5884423</ArticleId><ArticleId IdType="pubmed">29556029</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong GAB, Liao M, You Z, Lissouba A, Chen BE, Drapeau P. Homology directed knockin of point mutations in the zebrafish tardbp and fus genes in ALS using the CRISPR/Cas9 system. PLoS ONE. 2016;11(3):1&#x2013;10. doi: 10.1371/journal.pone.0150188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0150188</ArticleId><ArticleId IdType="pmc">PMC4773037</ArticleId><ArticleId IdType="pubmed">26930076</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimori K, Ishikawa M, Otomo A, Atsuta N, Nakamura R, Akiyama T, et al. Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent. Nat Med. 2018;24(10):1579&#x2013;1589. doi: 10.1038/s41591-018-0140-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0140-5</ArticleId><ArticleId IdType="pubmed">30127392</ArticleId></ArticleIdList></Reference><Reference><Citation>Egawa N, Kitaoka S, Tsukita K, Naitoh M, Takahashi K, Yamamoto T, et al. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci Transl Med. 2012;4(145):145ra104. doi: 10.1126/scitranslmed.3004052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3004052</ArticleId><ArticleId IdType="pubmed">22855461</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita M, Nonaka T, Hirai S, Miwa A, Okado H, Arai T, et al. Distinct pathways leading to TDP-43-induced cellular dysfunctions. Hum Mol Genet. 2014;23(16):4345&#x2013;4356. doi: 10.1093/hmg/ddu152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu152</ArticleId><ArticleId IdType="pubmed">24698978</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci USA. 2009;106(44):18809&#x2013;18814. doi: 10.1073/pnas.0908767106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0908767106</ArticleId><ArticleId IdType="pmc">PMC2762420</ArticleId><ArticleId IdType="pubmed">19833869</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreiter N, Pal A, Lojewski X, Corcia P, Naujock M, Reinhardt P, et al. Age-dependent neurodegeneration and organelle transport deficiencies in mutant TDP43 patient-derived neurons are independent of TDP43 aggregation. Neurobiol Dis. 2017;2018(115):167&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">29630989</ArticleId></ArticleIdList></Reference><Reference><Citation>Ichiyanagi N, Fujimori K, Yano M, Ishihara-Fujisaki C, Sone T, Akiyama T, et al. Establishment of in vitro FUS-associated familial amyotrophic lateral sclerosis model using human induced pluripotent stem cells. Stem Cell Rep. 2016;6(4):496&#x2013;510. doi: 10.1016/j.stemcr.2016.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2016.02.011</ArticleId><ArticleId IdType="pmc">PMC4834049</ArticleId><ArticleId IdType="pubmed">26997647</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimos JT, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, Chung W, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science. 2008;321(5893):1218&#x2013;1221. doi: 10.1126/science.1158799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1158799</ArticleId><ArticleId IdType="pubmed">18669821</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai S, Han L, Ao Q, Chan YS, Shum DKY. Human induced pluripotent cell-derived sensory neurons for fate commitment of bone marrow-derived Schwann cells: implications for remyelination therapy. Stem Cells Transl Med. 2017;6(2):369&#x2013;381. doi: 10.5966/sctm.2015-0424.</Citation><ArticleIdList><ArticleId IdType="doi">10.5966/sctm.2015-0424</ArticleId><ArticleId IdType="pmc">PMC5442799</ArticleId><ArticleId IdType="pubmed">28191772</ArticleId></ArticleIdList></Reference><Reference><Citation>Oki R, Izumi Y, Fujita K, Miyamoto R, Nodera H, Sato Y, et al. Efficacy and safety of ultrahigh-dose methylcobalamin in early-stage amyotrophic lateral sclerosis: a randomized clinical trial. JAMA Neurol. 2022;79(6):575&#x2013;583. doi: 10.1001/jamaneurol.2022.0901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2022.0901</ArticleId><ArticleId IdType="pmc">PMC9086935</ArticleId><ArticleId IdType="pubmed">35532908</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura K, Izumi Y, Nagai M, Nishiyama K, Watanabe Y, Hanajima R, et al. Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): a multicentre, open-label, dose-escalation phase 1 trial. EClinicalMedicine. 2022;53:101707. doi: 10.1016/j.eclinm.2022.101707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101707</ArticleId><ArticleId IdType="pmc">PMC9716331</ArticleId><ArticleId IdType="pubmed">36467452</ArticleId></ArticleIdList></Reference><Reference><Citation>Morimoto S, Takahashi S, Ito D, Dat&#xe9; Y, Okada K, Kato C, et al. Phase 1/2a clinical trial in ALS with ropinirole, a drug candidate identified by iPSC drug discovery. Cell Stem Cell. 2023;30(6):766&#x2013;780.e9. doi: 10.1016/j.stem.2023.04.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2023.04.017</ArticleId><ArticleId IdType="pubmed">37267913</ArticleId></ArticleIdList></Reference><Reference><Citation>Burkhardt MF, Martinez FJ, Wright S, Ramos C, Volfson D, Mason M, et al. A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells. Mol Cell Neurosci. 2013;56:355&#x2013;364. doi: 10.1016/j.mcn.2013.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2013.07.007</ArticleId><ArticleId IdType="pmc">PMC4772428</ArticleId><ArticleId IdType="pubmed">23891805</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves CJ, Dariolli R, Jorge FM, Monteiro MR, Maximino JR, Martins RS, et al. Gene expression profiling for human iPS-derived motor neurons from sporadic ALS patients reveals a strong association between mitochondrial functions and neurodegeneration. Front Cell Neurosci. 2015;9:1&#x2013;25. doi: 10.3389/fncel.2015.00289.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2015.00289</ArticleId><ArticleId IdType="pmc">PMC4523944</ArticleId><ArticleId IdType="pubmed">26300727</ArticleId></ArticleIdList></Reference><Reference><Citation>Okano H, Morimoto S. iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders. Cell Stem Cell. 2022;29(2):189&#x2013;208. doi: 10.1016/j.stem.2022.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2022.01.007</ArticleId><ArticleId IdType="pubmed">35120619</ArticleId></ArticleIdList></Reference><Reference><Citation>Deneault E, Chaineau M, Nicouleau M, Castellanos Montiel MJ, Franco Flores AK, Haghi G, et al. A streamlined CRISPR workflow to introduce mutations and generate isogenic iPSCs for modeling amyotrophic lateral sclerosis. Methods. 2022;203:297&#x2013;310. doi: 10.1016/j.ymeth.2021.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymeth.2021.09.002</ArticleId><ArticleId IdType="pubmed">34500068</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim BW, Ryu J, Jeong YE, Kim J, Martin LJ. Human motor neurons with SOD1-G93A mutation generated from CRISPR/Cas9 gene-edited iPSCs develop pathological features of amyotrophic lateral sclerosis. Front Cell Neurosci. 2020;14:1&#x2013;16. doi: 10.3389/fncel.2020.604171.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2020.604171</ArticleId><ArticleId IdType="pmc">PMC7710664</ArticleId><ArticleId IdType="pubmed">33328898</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammad M, Silva A, Glass J, Sladky JT, Benatar M. Clinical, electrophysiologic, and pathologic evidence for sensory abnormalities in ALS. Neurology. 2007;69(24):2236&#x2013;2242. doi: 10.1212/01.wnl.0000286948.99150.16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000286948.99150.16</ArticleId><ArticleId IdType="pubmed">18071143</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser F, Brandmeir NJ, Kwong LK, Martinez-Lage M, Elman L, McCluskey L, et al. Evidence of multisystem disorder in whole-brain map of pathological TDP-43 in amyotrophic lateral sclerosis. Arch Neurol. 2008;65(5):636&#x2013;641. doi: 10.1001/archneur.65.5.636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.65.5.636</ArticleId><ArticleId IdType="pubmed">18474740</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalla Bella E, Lombardi R, Porretta-Serapiglia C, Ciano C, Gellera C, Pensato V, et al. Amyotrophic lateral sclerosis causes small fiber pathology. Eur J Neurol. 2016;23(2):416&#x2013;420. doi: 10.1111/ene.12936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12936</ArticleId><ArticleId IdType="pubmed">26806218</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubio MA, Herrando-Grabulosa M, Navarro X. Sensory involvement in amyotrophic lateral sclerosis. Int J Mol Sci. 2022;23:15521. doi: 10.3390/ijms232415521.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232415521</ArticleId><ArticleId IdType="pmc">PMC9779879</ArticleId><ArticleId IdType="pubmed">36555161</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaughan SK, Sutherland NM, Zhang S, Hatzipetros T, Vieira F, Valdez G. The ALS-inducing factors, TDP43A315T and SOD1G93A, directly affect and sensitize sensory neurons to stress. Sci Rep. 2018;8(1):1&#x2013;12. doi: 10.1038/s41598-018-34510-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-34510-8</ArticleId><ArticleId IdType="pmc">PMC6224462</ArticleId><ArticleId IdType="pubmed">30410094</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Feng Y, Xue Y, Zhan X, Fu Y, Gui G, et al. Edaravone activates the GDNF/RET neurotrophic signaling pathway and protects mRNA-induced motor neurons from iPS cells. Mol Neurodegener. 2022;17(1):8. doi: 10.1186/s13024-021-00510-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-021-00510-y</ArticleId><ArticleId IdType="pmc">PMC8751314</ArticleId><ArticleId IdType="pubmed">35012575</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, Choi NY, Yu HJ, Park J, Choi H, Lee KY, et al. Atorvastatin protects NSC-34 motor neurons against oxidative stress by activating PI3K, ERK and free radical scavenging. Mol Neurobiol. 2016;53(1):695&#x2013;705. doi: 10.1007/s12035-014-9030-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-014-9030-0</ArticleId><ArticleId IdType="pubmed">25577170</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson K, Allen SP, Mortiboys H, Grierson AJ, Wharton SB, Ince PG, et al. The effect of SOD1 mutation on cellular bioenergetic profile and viability in response to oxidative stress and influence of mutation-type. PLoS ONE. 2013;8(6):e68256. doi: 10.1371/journal.pone.0068256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0068256</ArticleId><ArticleId IdType="pmc">PMC3695905</ArticleId><ArticleId IdType="pubmed">23840839</ArticleId></ArticleIdList></Reference><Reference><Citation>Dukkipati SS, Garrett TL, Elbasiouny SM. The vulnerability of spinal motoneurons and soma size plasticity in a mouse model of amyotrophic lateral sclerosis. J Physiol. 2018;596(9):1723&#x2013;1745. doi: 10.1113/JP275498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/JP275498</ArticleId><ArticleId IdType="pmc">PMC5924829</ArticleId><ArticleId IdType="pubmed">29502344</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Lewinski F, Keller BU. Ca2+, mitochondria and selective motoneuron vulnerability: implications for ALS. Trends Neurosci. 2005;28(9):494&#x2013;500. doi: 10.1016/j.tins.2005.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2005.07.001</ArticleId><ArticleId IdType="pubmed">16026864</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexianu ME, Ho BK, Mohamed AH, La Bella V, Smith RG, Appel SH. The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis. Ann Neurol. 1994;36(6):846&#x2013;858. doi: 10.1002/ana.410360608.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410360608</ArticleId><ArticleId IdType="pubmed">7998770</ArticleId></ArticleIdList></Reference><Reference><Citation>Spruill MM, Kuncl RW. Calbindin-D28K is increased in the ventral horn of spinal cord by neuroprotective factors for motor neurons. J Neurosci Res. 2015;93(8):1184&#x2013;1191. doi: 10.1002/jnr.23562.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.23562</ArticleId><ArticleId IdType="pubmed">25914366</ArticleId></ArticleIdList></Reference><Reference><Citation>Brockington A, Ning K, Heath PR, Wood E, Kirby J, Fusi N, et al. Unravelling the enigma of selective vulnerability in neurodegeneration: motor neurons resistant to degeneration in ALS show distinct gene expression characteristics and decreased susceptibility to excitotoxicity. Acta Neuropathol. 2013;125(1):95&#x2013;109. doi: 10.1007/s00401-012-1058-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-1058-5</ArticleId><ArticleId IdType="pmc">PMC3535376</ArticleId><ArticleId IdType="pubmed">23143228</ArticleId></ArticleIdList></Reference><Reference><Citation>Comley L, Allodi I, Nichterwitz S, Nizzardo M, Simone C, Corti S, et al. Motor neurons with differential vulnerability to degeneration show distinct protein signatures in health and ALS. Neuroscience. 2015;291:216&#x2013;229. doi: 10.1016/j.neuroscience.2015.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2015.02.013</ArticleId><ArticleId IdType="pubmed">25697826</ArticleId></ArticleIdList></Reference><Reference><Citation>Asakawa K, Handa H, Kawakami K. Multi-phaseted problems of TDP-43 in selective neuronal vulnerability in ALS. Cell Mol Life Sci. 2021;78(10):4453&#x2013;4465. doi: 10.1007/s00018-021-03792-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-021-03792-z</ArticleId><ArticleId IdType="pmc">PMC8195926</ArticleId><ArticleId IdType="pubmed">33709256</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling JP, Pletnikova O, Troncoso JC, Wong PC. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science. 2015;349(6248):650&#x2013;655. doi: 10.1126/science.aab0983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aab0983</ArticleId><ArticleId IdType="pmc">PMC4825810</ArticleId><ArticleId IdType="pubmed">26250685</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma XR, Prudencio M, Koike Y, Vatsavayai SC, Kim G, Harbinski F, et al. TDP-43 represses cryptic exon inclusion in the FTD&#x2013;ALS gene UNC13A. Nature. 2022;603(7899):124&#x2013;130. doi: 10.1038/s41586-022-04424-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04424-7</ArticleId><ArticleId IdType="pmc">PMC8891019</ArticleId><ArticleId IdType="pubmed">35197626</ArticleId></ArticleIdList></Reference><Reference><Citation>Baughn MW, Melamed Z, L&#xf3;pez-Erauskin J, Beccari MS, Ling K, Zuberi A, et al. Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies. Science. 2023;379(6637):1140&#x2013;1149. doi: 10.1126/science.abq5622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abq5622</ArticleId><ArticleId IdType="pmc">PMC10148063</ArticleId><ArticleId IdType="pubmed">36927019</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S, Oiwa K, Murata Y, Komine O, Sobue A, Endo F, et al. ALS-linked TDP-43M337V knock-in mice exhibit splicing deregulation without neurodegeneration. Mol Brain. 2020;13(1):13&#x2013;16. doi: 10.1186/s13041-020-0550-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-020-0550-4</ArticleId><ArticleId IdType="pmc">PMC6971932</ArticleId><ArticleId IdType="pubmed">31959210</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso A, Logroscino G, Jick SS, Hern&#xe1;n MA. Incidence and lifetime risk of motor neuron disease in the United Kingdom: a population-based study. Eur J Neurol. 2009;16(6):745&#x2013;751. doi: 10.1111/j.1468-1331.2009.02586.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2009.02586.x</ArticleId><ArticleId IdType="pmc">PMC3093130</ArticleId><ArticleId IdType="pubmed">19475756</ArticleId></ArticleIdList></Reference><Reference><Citation>Niccoli T, Partridge L, Isaacs AM. Ageing as a risk factor for ALS/FTD. Hum Mol Genet. 2017;26(R2):R105&#x2013;R113. doi: 10.1093/hmg/ddx247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx247</ArticleId><ArticleId IdType="pubmed">28977441</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo WM, Yoon J, Lee JH, Lee Y, Lee H, Geum D, et al. Modeling axonal regeneration by changing cytoskeletal dynamics in stem cell-derived motor nerve organoids. Sci Rep. 2022;12(1):1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8827082</ArticleId><ArticleId IdType="pubmed">35136073</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawada J, Kaneda S, Kirihara T, Maroof A, Levi T, Eggan K, et al. Generation of a motor nerve organoid with human stem cell-derived neurons. Stem Cell Rep. 2017;9(5):1441&#x2013;1449. doi: 10.1016/j.stemcr.2017.09.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2017.09.021</ArticleId><ArticleId IdType="pmc">PMC5831012</ArticleId><ArticleId IdType="pubmed">29107592</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861&#x2013;872. doi: 10.1016/j.cell.2007.11.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.11.019</ArticleId><ArticleId IdType="pubmed">18035408</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa M, Taniguchi Y, Senda S, Takizawa N, Ichisaka T, Asano K, et al. A novel efficient feeder-free culture system for the derivation of human induced pluripotent stem cells. Sci Rep. 2014;4:1&#x2013;7. doi: 10.1038/srep03594.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep03594</ArticleId><ArticleId IdType="pmc">PMC3884228</ArticleId><ArticleId IdType="pubmed">24399248</ArticleId></ArticleIdList></Reference><Reference><Citation>Naito Y, Hino K, Bono H, Ui-Tei K. CRISPRdirect: software for designing CRISPR/Cas guide RNA with reduced off-target sites. Bioinformatics. 2015;31(7):1120&#x2013;1123. doi: 10.1093/bioinformatics/btu743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btu743</ArticleId><ArticleId IdType="pmc">PMC4382898</ArticleId><ArticleId IdType="pubmed">25414360</ArticleId></ArticleIdList></Reference><Reference><Citation>Cradick TJ, Qiu P, Lee CM, Fine EJ, Bao G. COSMID: a web-based tool for identifying and validating CRISPR/Cas off-target sites. Mol Ther Nucleic Acids. 2014;3(12):e214. doi: 10.1038/mtna.2014.64.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mtna.2014.64</ArticleId><ArticleId IdType="pmc">PMC4272406</ArticleId><ArticleId IdType="pubmed">25462530</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki M, Kondo S, Pei Z, Maekawa A, Saito I, Kanegae Y. Preferable sites and orientations of transgene inserted in the adenovirus vector genome: the E3 site may be unfavorable for transgene position. Gene Ther. 2015;22(5):421&#x2013;429. doi: 10.1038/gt.2014.124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gt.2014.124</ArticleId><ArticleId IdType="pmc">PMC4424821</ArticleId><ArticleId IdType="pubmed">25588742</ArticleId></ArticleIdList></Reference><Reference><Citation>Pei Z, Kondo S, Kanegae Y, Saito I. Copy number of adenoviral vector genome transduced into target cells can be measured using quantitative PCR: application to vector titration. Biochem Biophys Res Commun. 2012;417(3):945&#x2013;950. doi: 10.1016/j.bbrc.2011.12.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2011.12.016</ArticleId><ArticleId IdType="pubmed">22202173</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci. 2011;14(4):459&#x2013;468. doi: 10.1038/nn.2779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2779</ArticleId><ArticleId IdType="pmc">PMC3094729</ArticleId><ArticleId IdType="pubmed">21358643</ArticleId></ArticleIdList></Reference><Reference><Citation>Tollervey JR, Curk T, Rogelj B, Briese M, Cereda M. Europe PMC Funders Group characterising the RNA targets and position-dependent splicing regulation by TDP-43; implications for neurodegenerative diseases. Nat Neurosci. 2011;14(4):452&#x2013;458. doi: 10.1038/nn.2778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2778</ArticleId><ArticleId IdType="pmc">PMC3108889</ArticleId><ArticleId IdType="pubmed">21358640</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>